ecodagЮг России: экология, развитиеSouth of Russia: ecology, development1992-10982413-0958State Institute of Applied Ecology of the Republic of Dagestan10.18470/1992-1098-2022-3-135-152ecodag-2586Research ArticleЭКОЛОГИЯ МИКРООРГАНИЗМОВИнгибирующая активность водных экстрактов чайных композиций, индивидуальных ингредиентов для их составления и некоторых растений на репликацию вируса простого герпеса 2 типа in vitroInhibitory activity of aqueous extracts of tea compositions, individual ingredients for their preparation and some plants against replication of Herpes simplex virus type 2 in vitrohttps://orcid.org/0000-0002-1856-6147КазачинскаяЕ. И.КаzachinskaiaE. I.

Казачинская Елена И. - доктор биологических наук, ведущий научный сотрудник ФИЦ ФТМ СО РАН.

630559, Новосибирск, р/п Кольцово 32‐1.

Тел. +79095307441

Elena I. Kazachinskaia - Doctor of Biology, Leading Researcher of the Research Institute of Virology, Federal Research Centre of Fundamental and Translational Medicine, Siberian Branch of Russian Academy of Sciences.

r/p Koltsovo 32‐1, Novosibirsk, 630559.

Tel. +79095307441

lena.kazachinskaia@mail.ruhttps://orcid.org/0000-0002-5966-8633ЧепурновА. А.ChepurnovA. A.

Чепурнов Александр А.

Новосибирск.

Alexander А. Chepurnov.

Novosibirsk.

https://orcid.org/0000-0001-7840-1478ШелембаА. А.ShelembaA. A.

Шелемба Арсения А.

Новосибирск.

Arseniya А. Shelemba.

Novosibirsk.

https://orcid.org/0000-0001-5634-2737ГусейноваС. A.GuseinovaS. A.

Гусейнова Сакинат А.

Махачкала.

Sakinat A. Guseinova.

Makhachkala.

https://orcid.org/0000-0003-1897-6784МагомедовМ. Г.MagomedovM. G.

Магомедов Магомед Г.

Махачкала.

Magomed G. Magomedov.

Makhachkala.

https://orcid.org/0000-0002-3677-3668КононоваЮ. В.КоnonovaYu. V.

Кононова Юлия В.

Новосибирск.

Yulia V. Коnonova.

Novosibirsk.

https://orcid.org/0000-0002-6860-9168РоманюкВ. В.RomanyukV. V.

Романюк Владимир В.

Новосибирск.

Vladimir V. Romanyuk.

Novosibirsk.

https://orcid.org/0000-0002-9734-0620ШестопаловА. М.ShestopalovA. M.

Шестопалов Александр М.

Новосибирск.

Аlexander М. Shestopalov.

Novosibirsk.

Научно‐исследовательский институт вирусологии Федерального исследовательского центра фундаментальной и трансляционной медицины» Cибирского отделения Российской Академии наук (ФИЦ ФТМ СО РАН)Research Institute of Virology, Federal Research Centre of Fundamental and Translational Medicine, Siberian Branch, Russian Academy of SciencesДагестанский государственный университетDagestan State UniversityДагестанский государственный медицинский университетDagestan State Medical UniversityНаучно‐производственная фирма (НПФ) «Золотая долина»Zolotaya Dolina Research and Production Company202209102022173135152Copyright © Казачинская Е.И., Чепурнов А.А., Шелемба А.А., Гусейнова С.A., Магомедов М.Г., Кононова Ю.В., Романюк В.В., Шестопалов А.М., 20222022Казачинская Е.И., Чепурнов А.А., Шелемба А.А., Гусейнова С.A., Магомедов М.Г., Кононова Ю.В., Романюк В.В., Шестопалов А.М.Каzachinskaia E.I., Chepurnov A.A., Shelemba A.A., Guseinova S.A., Magomedov M.G., Коnonova Y.V., Romanyuk V.V., Shestopalov A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ecodag.elpub.ru/ugro/article/view/2586Цель

Цель. Анализ in vitro ингибирующей активности водных экстрактов готовых   чайных   композиций,   растительного   сырья,   а   также растений из разных семейств на репликацию вируса простого герпеса 2 типа (HSV‐2).

Материал и методы

Материал и методы. Вирусный штамм MS HSV‐2 был пассирован на культуре  клеток  Vero.  Противовирусную  (ингибирующую) активность водных экстрактов исследовали in vitro по классической схеме нейтрализации (инактивации) вируса.

Результаты

Результаты.  При  сравнении  с  контрольными  образцами  водных экстрактов чаги и травы манжетки обыкновенной с 50%‐ми эффективными концентрациями, равными 21,36±3,92 и 39,67±8,75  мкг/мл  (по  сухому  сырью)  против  103 БОЕ/мл  HSV‐2, превосходящая    ингибирующая  активность  (от    15,25±3,92 до 1,71±0,54 мкг/мл) выявлена для экстрактов чайных композиций на основе черного и зеленого чая, а также индивидуальных ингредиентов для их составления – черного чая, листьев мяты перечной, цветов лаванды узколистной и специи гвоздики. Из экстрактов, полученных из растений, не входящих в состав готовых чайных композиций, интерес представляют ферментированные листья кипрея узколистного (Epilobium angustifolium L., Onagraceae) и трава молочая двух видов Euphorbia pilosa L. и E. esula L. (Euphorbiaceae)  с  ингибирующей  активностью  в  концентрациях 10,675±1,96; 2,29±0,57 и 1,71±0,54 мкг/мл, соответственно.

Заключение

Заключение. Представленные результаты могут стать основой для поиска индивидуальных биологически активных веществ растительного происхождения, ингибирующих репликацию HSV‐2, а  также  для  разработки  эффективных  лекарственных  препаратов виде чайных напитков и/или составов для местного применения для снижения рецидивов хронического герпеса.

Aim

Aim. In vitro analysis of the inhibitory activity of aqueous extracts of tea compositions, plant raw materials and as well as plants from different families against replication of Herpes simplex virus type 2.

Material and Methods

Material and Methods. The viral strain MS of HSV‐2 was passivated on Vero cell culture. Antiviral (inhibitory) activity of aqueous extracts was studied in vitro according to the classical scheme of neutralization (inactivation) of the virus.

Results

Results. For comparison we used control samples of aqueous extracts of Chaga mushroom (Inonotus obliquus) and grass of Alchemilla vulgaris L. with EC50 equal to 21.36±3.92 and 39.67±8.75 µg/ml (for dry raw materials) versus 103  PFU/ml HSV‐2. As a result the prevailing activity (from 15.25±3.92 to 1.71±0.54 µg/ml) was identified for extracts of tea compositions based on black and green tea, as well as individual ingredients for their composition – black tea, leaves of Mentha piperita L.,  flowers  of  Lavandula  angustifolia  Mill. and  clove  spices  (Syzygium aromaticum L.). Extracts obtained from plants that are not part of tea compositions of interest are fermented leaves of Epilobium angustifolium L. (Onagraceae) and grass of two species Euphorbia (E. pilosa L. and E. esula  L.,  Euphorbiaceae)  with  inhibitory  activity  at  concentrations  of 10.675±1.96; 2.29±0.57 and 1.71±0.54 µg/ml, respectively.

Conclusion

Conclusion. The results presented can become the basis for the search for individual biologically active substances of plant origin that inhibit HSV‐2 replication as well as for the development of effective medicines in the form of tea beverages and/or formulations for topical use to reduce relapses of chronic herpes.

Чайные композициирастительное сырьеводные экстрактыантивирусная активностьвирус простого герпеса 2 типа (Herpes simplex virus type 2HSV‐2)Tea compositionsraw materials of herbsaqueous extractsantiviral activityHerpes simplex virus type 2HSV‐2ReferencesAleem A., Akbar Samad A.B., Slenker A.K. Emerging Variants of SARS‐CoV‐2 And Novel Therapeutics Against Coronavirus (COVID‐19). 2022 May 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.Aleem A., Akbar Samad A.B., Slenker A.K. Emerging Variants of SARS‐CoV‐2 And Novel Therapeutics Against Coronavirus (COVID‐19). 2022 May 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.Abdoli A., Falahi S., Kenarkoohi A. COVID‐19‐associated opportunistic infections: a snapshot on the current reports // Clin Exp Med. 2022. V. 22. P. 327‐346. DOI: 10.1007/s10238‐021‐00751‐7Abdoli A., Falahi S., Kenarkoohi A. COVID‐19‐associated opportunistic infections: a snapshot on the current reports. Clin Exp Med., 2022, vol. 22, pp. 327‐346. DOI: 10.1007/s10238‐021‐00751‐7Franceschini E., Cozzi‐Lepri A., Santoro A., Bacca E., Lancellotti G., Menozzi M., Gennari W., Meschiari M., Bedini A., Orlando G., PuzzolanteC., Digaetano M., Milic J., Codeluppi M., Pecorari M., Carli F., Cuomo G., Alfano Gaetano, Corradi L., Tonelli R., De Maria N., Busani S., Biagioni E., Coloretti I., Guaraldi G., Sarti M., Luppi M., Clini E., Girardis M., Gyssens I.C., Mussini C. Herpes Simplex Virus Re‐Activation in Patients with SARS‐CoV‐2 Pneumonia: A Prospective, Observational Study // Microorganisms. 2021. V. 9. N 9. P. 1896. DOI: 10.3390/microorganisms9091896Franceschini E., Cozzi‐Lepri A., Santoro A., Bacca E., Lancellotti G., Menozzi M., Gennari W., Meschiari M., Bedini A., Orlando G., PuzzolanteC., Digaetano M., Milic J., Codeluppi M., Pecorari M., Carli F., Cuomo G., Alfano Gaetano, Corradi L., Tonelli R., De Maria N., Busani S., Biagioni E., Coloretti I., Guaraldi G., Sarti M., Luppi M., Clini E., Girardis M., Gyssens I.C., Mussini C. Herpes Simplex Virus Re‐Activation in Patients with SARS‐CoV‐2 Pneumonia: A Prospective, Observational Study. Microorganisms, 2021, vol. 9, no. 9, pp. 1896. DOI: 10.3390/microorganisms9091896Maia C.M.F., Marques N.P., de Lucena E.H.G., de Rezende L.F., Martelli D.R.B., Martelli‐Júnior H. Increased number of Herpes Zoster cases in Brazil related to the COVID‐19 pandemic // Int. J. Infect. Dis. 2021. N 104. P. 732‐733. DOI: 10.1016/j.ijid.2021.02.033Maia C.M.F., Marques N.P., de Lucena E.H.G., de Rezende L.F., Martelli D.R.B., Martelli‐Júnior H. Increased number of Herpes Zoster cases in Brazil related to the COVID‐19 pandemic. Int. J. Infect. Dis., 2021, no. 104, pp. 732‐733. DOI: 10.1016/j.ijid.2021.02.033Dursun R., Temiz S.A. The clinics of HHV‐6 infection in COVID‐19 pandemic: Pityriasis rosea and Kawasaki disease // Dermatol. Ther. 2020. N 33. e13730. DOI: 10.1111/dth.13730Dursun R., Temiz S.A. The clinics of HHV‐6 infection in COVID‐19 pandemic: Pityriasis rosea and Kawasaki disease. Dermatol. Ther., 2020, no. 33, e13730. DOI: 10.1111/dth.13730Seeßle J., Hippchen T., Schnitzler P., Gsenger J., Giese T., Merle U. High rate of HSV‐1 reactivation in invasively ventilated COVID‐19 patients: Immunological findings // PLoS ONE. 2021. V. 16. N 7. e0254129. DOI: 10.1371/journal.pone.0254129Seeßle J., Hippchen T., Schnitzler P., Gsenger J., Giese T., Merle U. High rate of HSV‐1 reactivation in invasively ventilated COVID‐19 patients: Immunological findings. PLoS ONE, 2021, vol. 16, no. 7, e0254129. DOI: 10.1371/journal.pone.0254129Lovati C., Osio M., Pantoni L. Diagnosing herpes simplex‐1 encephalitis at the time of COVID‐19 pandemic // Neurol Sci. 2020. V. 41. N 6. P. 1361‐1364. DOI: 10.1007/s10072‐020‐04461‐yLovati C., Osio M., Pantoni L. Diagnosing herpes simplex‐1 encephalitis at the time of COVID‐19 pandemic. Neurol Sci., 2020, vol. 41, no. 6, pp. 1361‐1364. DOI: 10.1007/s10072‐020‐04461‐yAlharthy A., Faqihi F., Noor A., Memish Z.A., Karakitsos D. Co‐infection of human immunodeficiency virus, herpes simplex virus‐2 and SARS‐CoV‐2 with false‐negative real‐time polymerase chain reaction // Singapore Med J. 2022. V. 63(6). P. 345‐347. DOI: 10.11622/smedj.2020158Alharthy A., Faqihi F., Noor A., Memish Z.A., Karakitsos D. Co‐infection of human immunodeficiency virus, herpes simplex virus‐2 and SARS‐CoV‐2 with false‐negative real‐time polymerase chain reaction. Singapore Med J., 2022, vol. 63(6), pp. 345‐347. DOI: 10.11622/smedj.2020158Al‐Dwairi R.A., Aleshawi A., Adi S., Abu‐Zreig L. Reactivation of Herpes Simplex Keratitis on a Corneal Graft Following SARS‐CoV‐2 mRNA Vaccination // Med Arch. 2022. V. 76. N 2. P. 146‐148. DOI: 10.5455/medarh.2022.76.146‐148Al‐Dwairi R.A., Aleshawi A., Adi S., Abu‐Zreig L. Reactivation of Herpes Simplex Keratitis on a Corneal Graft Following SARS‐CoV‐2 mRNA Vaccination. Med Arch., 2022, vol. 76, no. 2, pp. 146‐148. DOI: 10.5455/medarh.2022.76.146‐148Tognarelli E.I., Palomino T.F., Corrales N., Bueno S.M., Kalergis A.M., González P.A. Herpes Simplex Virus Evasion of Early Host Antiviral Responses // Front Cell Infect Microbiol. 2019. V. 9. pp. 127. DOI: 10.3389/fcimb.2019.00127TognarelliE.I., Palomino T.F., Corrales N., Bueno S.M., Kalergis A.M., González P.A. Herpes Simplex Virus Evasion of Early Host Antiviral Responses. Front Cell Infect Microbiol., 2019, vol. 9, pp. 127. DOI: 10.3389/fcimb.2019.00127Koelle D.M., Norberg P., Fitzgibbon M.P., Russell R.M., Greninger A.L., Huang M.‐L., Stensland L., Jing L., Magaret A.S., Diem K., Selke S., Xie H., Celum C., Lingappa J.R., Jerome K.R., Wald A., Johnston C. Worldwide circulation of HSV‐2 × HSV‐1 recombinant strains // Sci Rep. 2017. N 7. P. 44084. DOI: 10.1038/srep44084Koelle D.M., Norberg P., Fitzgibbon M.P., Russell R.M., Greninger A.L., Huang M.‐L., Stensland L., Jing L., Magaret A.S., Diem K., Selke S., Xie H., Celum C., Lingappa J.R., Jerome K.R., Wald A., Johnston C. Worldwide circulation of HSV‐2 × HSV‐1 recombinant strains. Sci Rep., 2017, no. 7, pp. 44084. DOI: 10.1038/srep44084Forni D., Pontremoli C., Clerici M., Pozzoli U., Cagliani R., Sironi M. Recent out‐of‐Africa migration of human herpes simplex viruses // Mol. Biol. Evol. 2020. N 37. P. 1259‐1271. DOI: 10.1093/molbev/msaa001Forni D., Pontremoli C., Clerici M., Pozzoli U., Cagliani R., Sironi M. Recent out‐of‐Africa migration of human herpes simplex viruses. Mol. Biol. Evol., 2020, no. 37, pp. 1259‐1271. DOI: 10.1093/molbev/msaa001James C., Harfouche M., Welton N.J., Turner K.M., Abu‐ Raddad L.J., Gottlieb S.L., Looker K.J. Herpes simplex virus: Global infection prevalence and incidence estimates, 2016 // Bull. World Health Organ. 2020. N 98. P. 315‐329. DOI: 10.2471/BLT.19.237149James C., Harfouche M., Welton N.J., Turner K.M., Abu‐Raddad L.J., Gottlieb S.L., Looker K.J. Herpes simplex virus: Global infection prevalence and incidence estimates, 2016. Bull. World Health Organ., 2020, no. 98, pp. 315‐329. DOI: 10.2471/BLT.19.237149Treml J., GazdováM., Šmejkal K., Šudomová M., Kubatka P., Hassan Sherif T.S. Natural Products‐Derived Chemicals: Breaking Barriers to Novel Anti‐HSV Drug Development // Viruses. 2020. V. 12. N 2. pp. 154. DOI: 10.3390/v12020154Treml J., Gazdová M., Šmejkal K., Šudomová M., Kubatka P., Hassan Sherif T.S. Natural Products‐Derived Chemicals: Breaking Barriers to Novel Anti‐HSV Drug Development. Viruses, 2020, vol. 12, no. 2, pp. 154. DOI: 10.3390/v12020154McQuillan G., Kruszon‐Moran D., Flagg E.W., Paulose‐Ram R. Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14‐49: United States, 2015‐2016 // NCHS Data Brief. 2018. N 304. P. 1‐8.McQuillan G., Kruszon‐Moran D., Flagg E.W., Paulose‐Ram R. Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14‐49: United States, 2015‐2016. NCHS Data Brief., 2018, no. 304, pp. 1‐8.Egan K.P., Wu S., Wigdahl B., Jennings S.R. Immunological control of herpes simplex virus infections // J. Neurovirol. 2013. N 19. P. 328‐345. DOI: 10.1007/s13365‐013‐0189‐3Egan K.P., Wu S., Wigdahl B., Jennings S.R. Immunological control of herpes simplex virus infections. J. Neurovirol., 2013, no. 19, pp. 328‐345. DOI: 10.1007/s13365‐013‐0189‐3Silhol R., Coupland H., Baggaley R.F., Miller L., Staadegaard L., Gottlieb S.L., Stannah J., Turner K.M.E., Vickerman P., Hayes R., Mayaud P., Looker K.J, Boily M.‐C. What is the burden of heterosexually‐acquired HIV due to HSV‐2? Global and regional model‐based estimates of the proportion and number of HIV infections attributable to HSV‐2 infection // J Acquir Immune Defic Syndr. 2021. V. 88. Iss. 1. P. 19‐30. DOI: 10.1097/QAI.0000000000002743Silhol R., Coupland H., Baggaley R.F., Miller L., Staadegaard L., Gottlieb S.L., Stannah J., Turner K.M.E., Vickerman P., Hayes R., Mayaud P., Looker K.J, Boily M.‐C. What is the burden of heterosexually‐acquired HIV due to HSV‐2? Global and regional model‐based estimates of the proportion and number of HIV infections attributable to HSV‐2 infection. J Acquir Immune Defic Syndr., 2021, vol. 88, iss. 1, pp. 19‐30. DOI: 10.1097/QAI.0000000000002743Mrаzovа V., Golais F.B. A Possible Role of Human Herpes Viruses Belonging to the Subfamily Alphaherpesvirinae in the Development of Some Cancers // Klin Onkol. Spring. 2018. V. 31. N 3. P. 178‐183. DOI: 10.14735/amko2018178Mrаzovа V., Golais F.B. A Possible Role of Human Herpes Viruses Belonging to the Subfamily Alphaherpesvirinae in the Development of Some Cancers. Klin Onkol. Spring., 2018, vol. 31, no. 3, pp. 178‐183. DOI: 10.14735/amko2018178AschnerC.B., Herold B.C. Alphaherpesvirus Vaccines // Curr Issues Mol Biol. 2021. N 41. P. 469‐508. DOI: 10.21775/cimb.041.469AschnerC.B., Herold B.C. Alphaherpesvirus Vaccines. Curr Issues Mol Biol., 2021, no. 41, pp. 469‐508. DOI: 10.21775/cimb.041.469Whitley R., Baines J. Clinical management of herpes simplex virus infections: Past, present, and future // F1000 Res. 2018. no. 7. F1000 Faculty Rev‐1726. DOI: 10.12688/f1000research.16157.1Whitley R., Baines J. Clinical management of herpes simplex virus infections: Past, present, and future. F1000 Res., 2018, no. 7. F1000 Faculty Rev‐1726. DOI: 10.12688/f1000research.16157.1Garber A., Barnard L., Pickrell C. Review of Whole Plant Extracts With Activity Against Herpes Simplex Viruses In Vitro and In Vivo // J Evid Based Integr Med. 2021. N 26. Article number: 2515690X20978394. DOI: 10.1177/2515690X20978394Garber A., Barnard L., Pickrell C. Review of Whole Plant Extracts With Activity Against Herpes Simplex Viruses In Vitro and In Vivo. J Evid Based Integr Med., 2021, no. 26, article number: 2515690X20978394. DOI: 10.1177/2515690X20978394Ding L., Jiang P., Xu X., Lu W., Yang C., Li L., Zhou P., Liu S. T‐ type calcium channels blockers inhibit HSV‐2 infection at the late stage of genome replication // Eur J Pharmacol. 2021. N 892. Article number: 173782. DOI: 10.1016/j.ejphar.2020.173782Ding L., Jiang P., Xu X., Lu W., Yang C., Li L., Zhou P., Liu S. T‐ type calcium channels blockers inhibit HSV‐2 infection at the late stage of genome replication. Eur J Pharmacol., 2021, no. 892, article number: 173782. DOI: 10.1016/j.ejphar.2020.173782Mucsi I., Gyulai Z., Béládi I. Combined effects of flavonoids and acyclovir against herpesviruses in cell cultures // Acta Microbiol Hung. 1992. V. 39. N 2. P. 137‐47.Mucsi I., Gyulai Z., Béládi I. Combined effects of flavonoids and acyclovir against herpesviruses in cell cultures. Acta Microbiol Hung., 1992, vol. 39, no. 2, pp. 137‐47.Mhatre S., Srivastava T., Naik S., Patravale V. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID‐19: A review // Phytomedicine. 2020. V. 85. Article number: 153286. DOI: 10.1016/j.phymed.2020.153286Mhatre S., Srivastava T., Naik S., Patravale V. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID‐19: A review. Phytomedicine, 2020, vol. 85, article number: 153286. DOI: 10.1016/j.phymed.2020.153286Musarra‐Pizzo M., Pennisi R., Ben‐Amor I., Smeriglio A., Mandalari G., Sciortino M.T. In Vitro Anti‐HSV‐1 Activity of Polyphenol‐Rich Extracts and Pure Polyphenol Compounds Derived from Pistachios Kernels (Pistacia vera L.) // Plants (Basel). 2020. V. 9. N 2. P. 267. DOI: 10.3390/plants9020267Musarra‐Pizzo M., Pennisi R., Ben‐Amor I., Smeriglio A., Mandalari G., Sciortino M.T. In Vitro Anti‐HSV‐1 Activity of Polyphenol‐Rich Extracts and Pure Polyphenol Compounds Derived from Pistachios Kernels (Pistacia vera L.). Plants (Basel), 2020, vol. 9, no. 2, pp. 267. DOI: 10.3390/plants9020267Cascella M., Bimonte S., Muzio M.R., Schiavone V., Cuomo A. The efficacy of Epigallocatechin‐3‐gallate (green tea) in the treatment of Alzheimer's disease: an overview of pre‐clinical studies and translational perspectives in clinical practice // Infect Agent Cancer. 2017. N 12. P. 36. DOI: 10.1186/s13027‐017‐0145‐6Cascella M., Bimonte S., Muzio M.R., Schiavone V., Cuomo A. The efficacy of Epigallocatechin‐3‐gallate (green tea) in the treatment of Alzheimer's disease: an overview of pre‐clinical studies and translational perspectives in clinical practice. Infect Agent Cancer., 2017, no. 12, pp. 36. DOI: 10.1186/s13027‐017‐0145‐6Zakaryan H., Arabyan E., Oo A., Zandi K. Flavonoids: promising natural compounds against viral infections // Arch Virol. 2017. V. 162. N 9. P. 2539‐2551. DOI: 10.1007/s00705‐017‐3417‐yZakaryan H., Arabyan E., Oo A., Zandi K. Flavonoids: promising natural compounds against viral infections. Arch Virol., 2017, vol. 162, no. 9, pp. 2539‐2551. DOI: 10.1007/s00705‐017‐3417‐yJo S., Kim S., Shin D.H., Kim M.‐S. Inhibition of SARS‐CoV 3CL protease by flavonoids // J Enzyme Inhib Med Chem. 2020. V. 35. N 1. P. 145‐151. DOI: 10.1080/14756366.2019.1690480Jo S., Kim S., Shin D.H., Kim M.‐S. Inhibition of SARS‐CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem., 2020, vol. 35, no. 1, pp. 145‐151. DOI: 10.1080/14756366.2019.1690480Mhatre S., Srivastava T., Naik S., Patravale V. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID‐19: A review // Phytomedicine. 2021. N 85. Article number: 153286. DOI: 10.1016/j.phymed.2020.153286Mhatre S., Srivastava T., Naik S., Patravale V. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID‐19: A review. Phytomedicine, 2021., no. 85, article number: 153286. DOI: 10.1016/j.phymed.2020.153286Казачинская Е.И., Чепурнов А.А., Кононова Ю.В., Шелемба А.А., Романюк В.В., Магомедов М.Г., Шестопалов А.М. Ингибирующая активность чайных композиций и их составляющих ингредиентов на репликацию SARS‐COV‐2 in vitro // Юг России: экология, развитие. 2022. Т. 17. N 2. C. 76‐90. DOI: 10.18470/1992‐1098‐2022‐2‐76‐9Каzachinskaia Е.I., Chepurnov А.А., Коnonova Yu.V., Shelemba А.А., Romanyuk V.V., Magomedov M.G., Shestopalov А.М. Inhibitory activity of tea compositions and their constituent ingredients on SARS‐COV‐2 replication in vitro. South of Russia: ecology, development, 2022, vol. 17, no. 2, pp. 76‐90. (In Russian) DOI: 10.18470/1992‐1098‐2022‐2‐76‐90Разумов И.А., Косогова Т.А., Казачинская Е.И., Пучкова Л.И., Щербакова Н.С., Горбунова И.А., Михайловская И.Н., Локтев В.Б., Теплякова Т.В. Противовирусная активность водных экстрактов и полисахаридных фракций, полученных из мицелия и плодовых тел высших грибов // Антибиотики и химиотерапия. 2010. Т. 55. N 9‐10. С. 14‐18.Razumov I.A., Kosogova T.A., Kazachinskaia E.I., Puchkova L.I., Shcherbakova N.C., Gorbunova I.A., Mikhailovskaya I.N., Loktev V.B., Teplyakova T.V. Antiviral activity of aqueous extracts and polysaccharide fractions obtained from mycelium and fruiting bodies of higher fungi. Antibiotiki i khimioterapiya [Antibiotics and chemotherapy]. 2010, vol. 55, no. 9‐10, pp. 14‐18. (In Russian)Мазуркова Н.А., Кукушкина Т.А., Высочина Г.И., Ибрагимова Ж.Б., Лобанова И.Е., Филиппова Е.И., Мазуркова О.Ю., Макаревич Е.В., Шишкина Л.Н., Агафонов А.П. Изучение противогерпетической активности экстрактов манжетки обыкновенной (Alchemilla vulgaris L.) // Разработка и регистрация лекарственных средств. 2016. Т. 1. N 14. С. 118‐127.Mazurkova N.A., Kukushkina T.A., Vysochina G.I., Ibragimova G.B., Lobanova I.E., Filippova E.I., Mazurkova O.Ju., Makarevich E.V., Shishkina L.N., Agafonov A.P. The study of the antiherpetic activity of extracts of the common cuff (Alchemilla vulgaris L.). Razrabotka i registratsiya lekarstvennykh sredstv [Drug development & registration]. 2016, vol. 1, no. 14, pp. 118‐127. (In Russian)Суслопаров М.А., Глотов А.Г., Глотова Т.И. Изучение эффективности лечебно‐профилактического действия сверхмалых доз антител к гамма интерферону на экспериментальной мышиной модели герпес‐вирусной инфекции // Антибиотики и химиотерапия. 2004. Т. 49. N 10. С. 3‐6.Susloparov M.A., Glotov A.G., Glotova T.I. To study the effectiveness of the therapeutic and prophylactic effect of ultra‐ low doses of antibodies to gamma interferon on an experimental mouse model of herpes virus infection. Antibiotiki i khimioterapiya [Antibiotics and chemotherapy]. 2004, vol. 49, no. 10, pp. 3‐6. (In Russian)Шаполова Е.Г., Ломовский О.И., Казачинская Е.И., Локтев В.Б., Теплякова Т.В. Антивирусная активность композитов диоксида кремния с полифенолами, полученных механохимическим методом из растительного сырья // Химико‐фармацевтический журнал. 2016. Т. 50. N 9. С. 25‐29.Shapolova E.G., Lomovsky O.I., Kazachinskaia E.I., Loktev V.B., Teplyakova T.V. Antiviral Activity of Silicon Dioxide Composites with Polyphenols Obtained by Mechanochemical Method from Plant Raw Materials. Khimiko‐farmatsevticheskii zhurnal [Chemico‐pharmaceutical J.]. 2016, vol. 50, no. 9, pp. 25‐29. (In Russian)Фисенко В.П. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ / Под ред. Минздрав РФ, ЗАО «ИИА «Ремедиум, Москва. 2000. 398 с.Fisenko V.P. Rukovodstvo po eksperimental'nomu (doklinicheskomu) izucheniyu novykh farmakologicheskikh veshchestv [Guidelines for experimental (preclinical) study of new pharmacological substances]. Moscow, 2000, 398 p. (In Russian)Hassan S.T.S., Berchova‐Bimova K., Šudomova M., Malanik M., Smejkal K., Rengasamy K.R.R. In Vitro Study of Multi‐Therapeutic Properties of Thymus bovei Benth. Essential Oil and Its Main Component for Promoting Their Use in Clinical Practice // J. Clin. Med. 2018. N 7. P. 283. DOI: 10.3390/jcm7090283Hassan S.T.S., Berchova‐Bimova K., Šudomova M., Malanik M., Smejkal K., Rengasamy K.R.R. In Vitro Study of Multi‐Therapeutic Properties of Thymus bovei Benth. Essential Oil and Its Main Component for Promoting Their Use in Clinical Practice. J. Clin. Med., 2018, no. 7, pp. 283. DOI: 10.3390/jcm7090283Cheng H.‐Y., Lin L.‐T., Huang H.‐H., Yang C.‐M., Lin C.‐C. Yin Chen Hao Tang, a Chinese prescription, inhibits both herpes simplex virus type‐1 and type‐2 infections in vitro // Antiviral Res. 2008. V. 77. N 1. P. 14‐19. DOI: 10.1016/j.antiviral.2007.08.012Cheng H.‐Y., Lin L.‐T., Huang H.‐H., Yang C.‐M., Lin C.‐C. Yin Chen Hao Tang, a Chinese prescription, inhibits both herpes simplex virus type‐1 and type‐2 infections in vitro. Antiviral Res., 2008, vol. 77, no. 1, pp. 14‐19. DOI: 10.1016/j.antiviral.2007.08.012Churqui M.P., Lind L., Thörn K., Svensson A., Savolainen O., Aranda K.T., Kristina E. Extracts of Equisetum giganteum L. and Copaifera reticulate Ducke show strong antiviral activity against the sexually transmitted pathogen herpes simplex virus type 2 // J Ethnopharmacol. 2018. N 210. P. 192‐197. DOI: 10.1016/j.jep.2017.08.010Churqui M.P., Lind L., Thörn K., Svensson A., Savolainen O., Aranda K.T., Kristina E. Extracts of Equisetum giganteum L. and Copaifera reticulate Ducke show strong antiviral activity against the sexually transmitted pathogen herpes simplex virus type 2. J Ethnopharmacol., 2018, no. 210, pp. 192‐197. DOI: 10.1016/j.jep.2017.08.010Lu Y., Jia Y., Xue Z., Li N., Liu J., Chen H. Recent Developments in Inonotus obliquus (Chaga mushroom) Polysaccharides: Isolation, Structural Characteristics, Biological Activities and Application // Polymers (Basel). 2021. V. 13. N 9. P. 1441. DOI: 10.3390/polym13091441Lu Y., Jia Y., Xue Z., Li N., Liu J., Chen H. Recent Developments in Inonotus obliquus (Chaga mushroom) Polysaccharides: Isolation, Structural Characteristics, Biological Activities and Application. Polymers (Basel), 2021, vol. 13, no. 9, pp. 1441. DOI: 10.3390/polym13091441Luganini A., Sibille G., Mognetti B., Sainas S., Pippione A.C., Giorgis M., Boschi D., Lolli M.L., Gribaudo G. Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication // Antiviral Res. 2021. V. 189. Article number: 105057. DOI: 10.1016/j.antiviral.2021.105057Luganini A., Sibille G., Mognetti B., Sainas S., Pippione A.C., Giorgis M., Boschi D., Lolli M.L., Gribaudo G. Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication. Antiviral Res., 2021, vol. 189, article number: 105057. DOI: 10.1016/j.antiviral.2021.105057Hassan S.T.S, Švajdlenka E., Berchová‐Bímová K. Hibiscus sabdariffa L. and Its Bioactive Constituents Exhibit Antiviral Activity against HSV‐2 and Anti‐enzymatic Properties against Urease by an ESI‐MS Based Assay // Molecules. 2017. V. 22. N 5. P. 722. DOI: 10.3390/molecules22050722Hassan S.T.S, Švajdlenka E., Berchová‐Bímová K. Hibiscus sabdariffa L. and Its Bioactive Constituents Exhibit Antiviral Activity against HSV‐2 and Anti‐enzymatic Properties against Urease by an ESI‐MS Based Assay. Molecules, 2017, vol. 22, no. 5, pp. 722. DOI: 10.3390/molecules22050722Krummenacher C., Baribaud F., de Leon M.P., Baribaud I., Whitbeck J.C., Xu R., Cohen G. H., Eisenberg R.J. Comparative usage of herpesvirus entry mediator A and nectin‐1 by laboratory strains and clinical isolates of herpes simplex virus // Virology. 2004. V. 322. N 2. P. 286‐299. DOI: 10.1016/j.virol.2004.02.005Krummenacher C., Baribaud F., de Leon M.P., Baribaud I., Whitbeck J.C., Xu R., Cohen G. H., Eisenberg R.J. Comparative usage of herpesvirus entry mediator A and nectin‐1 by laboratory strains and clinical isolates of herpes simplex virus. Virology, 2004, vol. 322, no. 2, pp. 286‐299. DOI: 10.1016/j.virol.2004.02.005Arduino P.G., Porter S.R. Herpes Simplex Virus Type 1 infection: Overview on relevant clinico‐pathological features // J. Oral Pathol. Med. 2008. V. 37. P. 107‐121. DOI: 10.1111/j.1600‐0714.2007.00586.xArduino P.G., Porter S.R. Herpes Simplex Virus Type 1 infection: Overview on relevant clinico‐pathological features. J. Oral Pathol. Med., 2008, vol. 37, pp. 107‐121. DOI: 10.1111/j.1600‐0714.2007.00586.xJambunathan N., Clark C.M., MusarratF., Chouljenko V.N., Rudd J., Kousoulas K.G. Two Sides to Every Story: Herpes Simplex Type‐1 Viral Glycoproteins gB, gD, gH/gL, gK, and Cellular Receptors Function as Key Players in Membrane Fusion // Viruses. 2021. V. 13. N 9. P. 1849. DOI: 10.3390/v13091849Jambunathan N., Clark C.M., Musarrat F., Chouljenko V.N., Rudd J., Kousoulas K.G. Two Sides to Every Story: Herpes Simplex Type‐1 Viral Glycoproteins gB, gD, gH/gL, gK, and Cellular Receptors Function as Key Players in Membrane Fusion. Viruses, 2021, vol. 13, no. 9, pp. 1849. DOI: 10.3390/v13091849Smith G.A. Navigating the Cytoplasm: Delivery of the Alphaherpesvirus Genome to the Nucleus // Curr Issues Mol Biol. 2021. N 41. P. 171‐220. DOI: 10.21775/cimb.041.171Smith G.A. Navigating the Cytoplasm: Delivery of the Alphaherpesvirus Genome to the Nucleus. Curr Issues Mol Biol., 2021, no. 41, pp. 171‐220. DOI: 10.21775/cimb.041.171Connolly S.A., Jardetzky T.S., Longnecker R. The structural basis of herpesvirus entry // Nat Rev Microbiol. 2021. V. 19. N 2. P. 110‐121. DOI: 10.1038/s41579‐020‐00448‐wConnolly S.A., Jardetzky T.S., Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol., 2021, vol. 19, no. 2, pp. 110‐121. DOI: 10.1038/s41579‐020‐00448‐wDemirS., Atayoglu A.T., Galeotti F., Garzarella E.U., Zaccaria V., Volpi N., Karagoz A.,Sahin F. Antiviral activity of different extracts of standardized propolis preparations against HSV // Antivir Ther. 2020. V. 25. N 7. P. 353‐363. DOI: 10.3851/IMP3383DemirS., Atayoglu A.T., Galeotti F., Garzarella E.U., Zaccaria V., Volpi N., Karagoz A., Sahin F. Antiviral activity of different extracts of standardized propolis preparations against HSV. Antivir Ther., 2020, vol. 25, no. 7, pp. 353‐363. DOI: 10.3851/IMP3383Mohan S.,Taha M.M.E., Makeen H.A., Alhazmi H.A., Bratty M.A., Sultana S., Ahsan W.,Najmi A., Khalid A. Bioactive Natural Antivirals: An Updated Review of the Available Plants and Isolated Molecules // Molecules. 2020. V. 25. N 21. P. 4878. DOI: 10.3390/molecules25214878Mohan S., Taha M.M.E., Makeen H.A., Alhazmi H.A., Bratty M.A., Sultana S., Ahsan W.,Najmi A., Khalid A. Bioactive Natural Antivirals: An Updated Review of the Available Plants and Isolated Molecules. Molecules, 2020, vol. 25, no. 21, pp. 4878. DOI: 10.3390/molecules25214878Benzekri R., Bouslama L., Papetti A., Hammami M., Smaoui A., Limam F. Anti HSV‐2 activity of Peganum harmala (L.) and isolation of the active compound // Microb Pathog. 2018. N 114. P. 291‐298. DOI: 10.1016/j.micpath.2017.12.017Benzekri R., Bouslama L., Papetti A., Hammami M., Smaoui A., Limam F. Anti HSV‐2 activity of Peganum harmala (L.) and isolation of the active compound. Microb Pathog., 2018, no. 114, pp. 291‐298. DOI: 10.1016/j.micpath.2017.12.017Donalisio M., Cagno V., Civra A., Gibellini D., Musumeci G., Rittà M., Ghosh M., Lembo D. The traditional use of Vachellia nilotica for sexually transmitted diseases is substantiated by the antiviral activity of its bark extract against sexually transmitted viruses // J Ethnopharmacol. 2018. N 213. P. 403‐408. DOI: 10.1016/j.jep.2017.11.039DonalisioM., Cagno V., Civra A., Gibellini D., Musumeci G., Rittà M., GhoshM., Lembo D. The traditional use of Vachellia nilotica for sexually transmitted diseases is substantiated by the antiviral activity of its bark extract against sexually transmitted viruses. J Ethnopharmacol, 2018, no. 213, pp. 403‐408. DOI: 10.1016/j.jep.2017.11.039Ojha D., Das R., Sobia P., Dwivedi V., Ghosh S., Samanta A., Chattopadhyay D. Pedilanthus tithymaloides Inhibits HSV Infection by Modulating NF‐κB Signaling // PLoS One. 2015. V. 10. N 9. e0139338. DOI: 10.1371/journal.pone.0139338Ojha D., Das R., Sobia P., Dwivedi V., Ghosh S., Samanta A., Chattopadhyay D. Pedilanthus tithymaloides Inhibits HSV Infection by Modulating NF‐κB Signaling. PLoS One, 2015, vol. 10, no. 9, e0139338. DOI: 10.1371/journal.pone.0139338Zannella C., Giugliano R., Chianese A., Buonocore C., Vitale G.A., Sanna G., Sarno F., Manzin A., Nebbioso A., Termolino P., Altucci L., Massimiliano G., de Pascale D., Franci G. Antiviral Activity of Vitis vinifera Leaf Extract against SARS‐CoV‐2 and HSV‐1 // Viruses. 2021. V. 13. N 7. P. 1263. DOI: 10.3390/v13071263Zannella C., Giugliano R., Chianese A., Buonocore C., Vitale G.A., Sanna G., Sarno F., Manzin A., Nebbioso A., Termolino P., Altucci L., Massimiliano G., de Pascale D., Franci G. Antiviral Activity of Vitis vinifera Leaf Extract against SARS‐CoV‐2 and HSV‐1. Viruses, 2021, vol. 13, no. 7, pp. 1263. DOI: 10.3390/v13071263Теплякова Т.В., Пьянков О.В., Скарнович М.О., Бормотов Н.И., Потешкина А.Л., Овчинникова А.С., Косогова Т.А., Магеррамова А.В., Маркович Н.А., Филиппова Е.И. Ингибитор репликации коронавируса SARS‐CoV‐2 на основе водного экстракта гриба Inonotus obliquus. // Пат. РФ N 2741714С1; опубл. 28.01.2021 в Бюл. N 4.Тeplyakova T.V., Pyankov O.V., Skarnovich M.O., Bormotov N.I., Poteshkina A.L., Ovchinnikova A.S., Kosogova T.A., Magerramova A.V., Markovich N.A., Filippova E.I. An inhibitor of SARS‐CoV‐2 coronavirus replication based on an aqueous extract of the fungus Inonotus obliquus. Patent of the Russian Federation no. 2741714C1 published in Bulletin of Inventions no. 4 28.01.2021. (In Russian)

The authors declare that there are no conflicts of interest present.